Quantcast

Industry news that matters to you.  Learn more

Biomarker Promise for Parkinson’s Disease

Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of research into disease-modifying treatments for neurodegenerative diseases. Although important strides have been made in biomarker research, for Parkinson’s disease (PD) as for other diseases, no validated, inexpensive, and simple markers are available. The launch of the Parkinson’s Progression Markers Initiative (PPMI), a public-private partnership spearheaded by the Michael J. Fox Foundation that aims to identify clinical, imaging, and biological markers of disease progression is therefore welcome news. But what do patients and the research community stand to gain from this initiative and can it fullfil its promise?

CROs Join with MJFF for Parkinson’s Biomarker Research

Covance, Parexel and Epitomics are working with the Michael J Fox Foundation for Parkinson’s Research (MJFF) to develop biomarker candidates.

Initiation of the projects is part of efforts by MJFF to progress biomarker research. MJFF said there is “urgent need for an orchestrated, fieldwide strategy to drive tangible progress” in the sector and contract research organisations (CRO) have a role to play in this initiative.

Michael J. Fox Foundation Announces $1.1 Million to Advance Leading Biomarker Candidates for Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson’s disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.